Supplementary Methods, Figure Legends, Tables 1 - 2, Figures 1 - 7 from VR23: A Quinoline–Sulfonyl Hybrid Proteasome Inhibitor That Selectively Kills Cancer via Cyclin E–Mediated Centrosome Amplification
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Materials and Methods for cloning and sulforhodamine B (SRB) assay, analysis of cell cycle distribution, knockdown of cyclin E with siRNA, EdU labelling, molecular docking modeling, and reagents. Supplementary Table S1. VR23 sensitizes paclitaxel-mediated cell killing, as determined by a clonogenic assay of MCF7 cancer cells. Supplementary Table S2. Examination of VR23-induced toxicity, as determined by the levels of ALT (alanine aminotransferase) and AST (aspartate aminotransferase) in ATH490 athymic mice. Supplementary Figure S1. VR23 induces apoptosis in a cancer cell-specific manner. Figure S2. VR23 induces cell cycle arrest in prometaphase and, eventually, apoptosis through the p38 MAPK pathway. Supplementary Figure S3. Cells exposed to VR23 show a variety of different abnormal phenotypes. Supplementary Figure S4. In MCF10A, cyclin E is heavily ubiquitinated in response to bortezomib (Borz), but not to VR23 or MG132. Supplementary Figure S5. VR23 shows effective antitumor activity in mice engrafted with RPMI 8226. Supplementary Figure S6. VR23 does not show any notable adverse effects to animals. Supplementary Figure S7. VR23 does not cause any notable ill-effects on vital organs as determined by their weights.
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361237485
